(5-bromo-2-isopropoxyphenyl)methanol | 562840-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (5-bromo-2-isopropoxyphenyl)methanol
• 英文别名: 5-bromo-2-isopropoxybenzyl alcohol；(5-bromo-2-propan-2-yloxyphenyl)methanol
• CAS: 562840-58-8
• 化学式: C₁₀H₁₃BrO₂
• 分子量: 245.116
• InChiKey: BJRLCGPOCZJPSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-bromo-2-isopropoxyphenyl)methanol 在 四(三苯基膦)钯 、 臭氧 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 24.0h， 生成 3-(羟基甲基)-4-异丙氧基苯甲醛
  参考文献：
  名称：

  [EN] BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF
  [FR] DÉRIVÉS DE BENZO[C][2,6]NAPHTYRIDINE, COMPOSITIONS ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein R1, Q, Ra, Rb, Rc, Rd and Re are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.

  公开号：

  WO2022185041A1
• 作为产物：
  描述：

  2-碘代丙烷 、 5-溴-2-羟基苯甲醇 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以74.5 %的产率得到(5-bromo-2-isopropoxyphenyl)methanol
  参考文献：
  名称：

  [EN] BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF
  [FR] DÉRIVÉS DE BENZO[C][2,6]NAPHTYRIDINE, COMPOSITIONS ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein R1, Q, Ra, Rb, Rc, Rd and Re are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.

  公开号：

  WO2022185041A1

文献信息

• Nitrogeneous cyclic ketone derivative, process for producing the same, and use
  申请人：Yamaoka Masayoshi

  公开号：US20050038072A1

  公开（公告）日：2005-02-17

  A novel compound represented by the formula (I): wherein rings A and B each represents an optionally substituted aromatic ring, or rings A and B may be bonded to each other through linking between bonds or substituents thereof to form a ring; ring C represents a nitrogenous saturated heterocycle optionally having one or more substituents besides the oxo (provided that 2,3-dioxopyrrolidine ring is excluded); R 1 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; and indicates a single bond or a double bond. It has high antagonistic activity against a tachykinin receptor, especially an SP receptor.

  一种新的化合物，化学式表示为（I）：其中环A和环B分别代表一个可选取代芳香环，或者环A和环B通过键或它们的取代基之间的连接结合形成一个环；环C代表一个氮饱和杂环，除了氧代（提供2,3-二氧代吡咯烷环除外）之外，还可以选择具有一个或多个取代基；R1代表氢、可选取代的碳氢基团或可选取代的杂环基团；表示单键或双键。它对一种快速激动肽受体，尤其是SP受体具有高拮抗活性。
• NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1460062A1

  公开（公告）日：2004-09-22

  A novel compound represented by the formula (I): wherein rings A and B each represents an optionally substituted aromatic ring, or rings A and B may be bonded to each other through linking between bonds or substituents thereof to form a ring; ring C represents a nitrogenous saturated heterocycle optionally having one or more substituents besides the oxo (provided that 2,3-dioxopyrrolidine ring is excluded); R1 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; and --------¯ indicates a single bond or a double bond. It has high antagonistic activity against a tachykinin receptor, especially an SP receptor.

  一种由式(I)代表的新型化合物： 其中，环 A 和环 B 各自代表一个任选取代的芳香环，或环 A 和环 B 可通过其键或取代基之间的连接而相互键合，形成一个环；环 C 代表一个含氮饱和杂环，除了氧代外，还可任选具有一个或多个取代基（前提是不包括 2,3-二氧代吡咯烷环）；R1 代表氢、任选取代的烃基或任选取代的杂环基；以及 --------¯ 表示单键或双键。它对速激肽受体，尤其是 SP 受体具有很高的拮抗活性。
• HERBIZID WIRKSAME 3-PHENYLISOXAZOLINDERIVATE
  申请人：Bayer CropScience AG

  公开号：EP2900645A1

  公开（公告）日：2015-08-05